ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

8:30AM-10:30AM: Abstract Number: 0434

Protein Profiling in Pre-dating Samples Separate MPO-ANCA Vasculitis from PR3-ANCA Vasculitis

Vasculitis – ANCA-Associated Poster (0414–0436)

8:30AM-10:30AM: Abstract Number: 0241

Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA

Pediatric Rheumatology – Clinical Poster I: JIA (0241–0265)

8:30AM-10:30AM: Abstract Number: 0046

Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts

Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

8:30AM-10:30AM: Abstract Number: 0267

Psychosocial and Health Measures in Systemic Lupus Erythematosus: Before and During the COVID-19 Pandemic in the Georgian’s Organized Against Lupus Cohort

Psychology/Social Sciences Poster (0266–0267)

8:30AM-10:30AM: Abstract Number: 0276

Pulse Pressure as a Predictor of Carotid Plaque in Rheumatoid Arthritis Patients

RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

8:30AM-10:30AM: Abstract Number: 0213

Quantitative Assessment of Volumetric Change in Hip Effusion Using Artificial Intelligence in Patients with Osteoarthritis of the Hip

Osteoarthritis – Clinical Poster I (0210–0224)

8:30AM-10:30AM: Abstract Number: 0272

RA Disease Activity Is an Independent Predictor of Left Ventricular Mass Changes in an RA Cohort Without Cardiovascular Disease

RA – Diagnosis, Manifestations, & Outcomes Poster I: Cardiovascular Pulmonary Disease (0268–0295)

8:30AM-10:30AM: Abstract Number: 0329

Racial and Ethnic Disparities in Risk of End-Organ Disease Following SLE Diagnosis in a Multi-Ethnic Cohort

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0342

RAIL Distinguishes Responder and Non-Responder in Pediatric Lupus Nephritis

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0199

Rapid Improvement in Cystoid Macular Edema with High Dose Intravenous Methylprednisolone in Non-Infectious Uveitis of Different Immune Mediated Inflammatory Diseases

Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

8:30AM-10:30AM: Abstract Number: 0337

Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Diagnosis (0323–0356)

8:30AM-10:30AM: Abstract Number: 0113

Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease

Epidemiology & Public Health Poster I: COVID-19 & Vaccination (0084–0117)

8:30AM-10:30AM: Abstract Number: 0129

Real-World Flare Rates and Progression by Treatment Settings Among the Commercially-Insured Systemic Lupus Erythematosus Population in the U.S

Health Services Research Poster I: Lupus, Inflammatory Arthritis, & More (0128–0148)

8:30AM-10:30AM: Abstract Number: 0231

Reducing the Number of Outpatient Clinic Visits by Using the Routine Assessment of Patient Index Data 3 as a Screening Tool

Patient Outcomes, Preferences, & Attitudes Poster I: Impact (0225–0240)

8:30AM-10:30AM: Abstract Number: 0220

Relation of Knee Extensor Power to Worsening Cartilage Damage in the Knee: The MOST Study

Osteoarthritis – Clinical Poster I (0210–0224)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].